Does second-line therapy affect the radiological progression of rheumatoid arthritis?

PubWeight™: 1.69‹?› | Rank: Top 3%

🔗 View Article (PMC 1001209)

Published in Ann Rheum Dis on February 01, 1984

Authors

T Pullar, J A Hunter, H A Capell

Articles citing this

A rheumatological dilemma: is it possible to modify the course of rheumatoid arthritis? Can we answer the question? Ann Rheum Dis (1985) 1.50

Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis (1987) 1.29

Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy. Ann Rheum Dis (1986) 1.11

A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis. Ann Rheum Dis (1986) 0.92

Pharmacological studies of antigen-induced arthritis in BALB/c mice. II. The effects of second-line antirheumatic drugs and cytotoxic agents on the histopathological changes. Agents Actions (1986) 0.86

Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow? Br J Clin Pharmacol (1990) 0.85

A rheumatological dilemma. Ann Rheum Dis (1985) 0.75

Combination chemotherapy in rheumatoid arthritis. Ann Rheum Dis (1991) 0.75

Destructive arthropathy after successful renal transplantation. Ann Rheum Dis (1990) 0.75

Managing early presentation of rheumatoid arthritis. Systematic overview. Can Fam Physician (1996) 0.75

Radiological evaluation of erosions: a quantitative method for assessing long-term remittive therapy in rheumatoid arthritis. Br J Clin Pharmacol (1986) 0.75

Disease remission in rheumatoid arthritis. Ann Rheum Dis (1989) 0.75

The use of disease modifying antirheumatic drugs in the management of rheumatoid arthritis. Postgrad Med J (1989) 0.75

Assessing the progression of joint damage in rheumatoid arthritis. Drugs (1986) 0.75

Calcaneus bone mineral density in Japanese women with rheumatoid arthritis. Rheumatol Int (2004) 0.75

Articles by these authors

Cardiac outcome after peripheral vascular surgery. Comparison of general and regional anesthesia. Anesthesiology (1996) 3.65

Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) (1983) 2.63

Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet (1991) 2.37

Cutaneous malignant melanoma, Scotland, 1979-89. The Scottish Melanoma Group. Lancet (1992) 2.31

Malignant melanoma in Scotland 1979-1983. Lancet (1985) 2.30

Excision biopsy of malignant melanoma by general practitioners in south east Scotland 1982-91. BMJ (1992) 2.14

Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94. The Scottish Melanoma Group. BMJ (1997) 2.08

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis (1993) 2.05

Illiteracy in rheumatoid arthritis patients as determined by the Rapid Estimate of Adult Literacy in Medicine (REALM) score. Rheumatology (Oxford) (2002) 2.00

Antibodies to neutrophil cytoplasmic antigens: serologic marker for Sweet's syndrome. J Am Acad Dermatol (1991) 1.98

Antiprostaglandin synthetase activity of nonsteroidal anti-inflammatory drugs and gastrointestinal micro-bleeding: a comparison of flurbiprofen with benoxaprofen. Ann Rheum Dis (1981) 1.97

What should we hope to achieve when treating rheumatoid arthritis? Ann Rheum Dis (1989) 1.89

Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) (1986) 1.88

Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis (1997) 1.87

BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) (2006) 1.86

Post-irradiation morphoea. Br J Dermatol (1989) 1.69

Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis (2004) 1.69

Leg wound complications associated with coronary revascularization. J Thorac Cardiovasc Surg (1981) 1.67

Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.63

Predominant generation of 15-lipoxygenase metabolites of arachidonic acid by epithelial cells from human trachea. Proc Natl Acad Sci U S A (1985) 1.59

Xanthomatosis secondary to lymphoedema. Trans St Johns Hosp Dermatol Soc (1970) 1.59

A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol (1999) 1.57

Nonsteroidal peptic damage in rheumatoid patients receiving second-line drugs. Am J Gastroenterol (1991) 1.57

Circular chloroplast DNA from Euglena gracilis. Proc Natl Acad Sci U S A (1971) 1.57

Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) (1986) 1.55

Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J (Clin Res Ed) (1985) 1.51

A rheumatological dilemma: is it possible to modify the course of rheumatoid arthritis? Can we answer the question? Ann Rheum Dis (1985) 1.50

Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med (1998) 1.50

Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis (1985) 1.49

Neurological abnormalities following open-heart surgery. J Thorac Cardiovasc Surg (1969) 1.48

Alteration of thiol and superoxide dismutase status in rheumatoid arthritis treated with sulphasalazine. Br J Rheumatol (1987) 1.45

Variations among rheumatologists in prescribing and monitoring of disease modifying antirheumatoid drugs. Br J Rheumatol (1992) 1.43

The 'natural' history of active rheumatoid arthritis over 3-6 months--an analysis of patients enrolled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placebo. Br J Rheumatol (1993) 1.42

Antineutrophil cytoplasmic antibody titres in patients with recent infection. Br J Rheumatol (1993) 1.42

The treatment of plantar warts in the home. A critical appraisal of a new preparation. Practitioner (1971) 1.42

Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma. BMJ (1988) 1.41

A case of orbital myositis associated with rheumatoid arthritis. Ann Rheum Dis (2002) 1.40

Methotrexate toxicity induced by acute renal failure. J R Soc Med (2004) 1.39

Fibrin-ring granulomas: a non-specific reaction to liver injury? Histopathology (1991) 1.39

Rupture of an otherwise normal aortic valve. Report of two cases and review of the literature. J Thorac Cardiovasc Surg (1968) 1.39

Predictive value of interleukin 1 gene polymorphisms for surgery. Ann Rheum Dis (2000) 1.38

The dermatology out-patient service: a study of out-patient referrals in a Scottish population. Br J Dermatol (1984) 1.38

Sweet's syndrome: a clinicopathologic review of twenty-nine cases. J Am Acad Dermatol (1990) 1.36

Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet (1989) 1.34

The use of the Internet as a resource for health information among patients attending a rheumatology clinic. Rheumatology (Oxford) (2002) 1.33

Sulphasalazine: a 'new' antirheumatic drug. Br J Rheumatol (1984) 1.30

Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br J Rheumatol (1985) 1.30

Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis (1987) 1.29

Seventeen-year experience with routine shunting in carotid artery surgery. World J Surg (1979) 1.28

Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum (2008) 1.24

En bloc resection of colon cancer adherent to other organs. Am J Surg (1987) 1.23

A neutral protease in rheumatoid synovial fluid capable of attacking the telopeptide regions of polymeric collagen fibrils. Biochim Biophys Acta (1975) 1.23

A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis (1991) 1.20

A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance by volunteers. Br J Clin Pharmacol (1990) 1.19

Clinical and laboratory studies of levamisole in patients with rheumatoid arthritis. Q J Med (1978) 1.19

Giant hogweed dermatitis. Scott Med J (1970) 1.19

N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy? Br J Clin Pharmacol (1987) 1.18

Synthesis of macromolecules during induction of haemoglobin synthesis by erythropoietin. J Mol Biol (1969) 1.18

The gene responsible for Werner syndrome may be a cell division "counting" gene. Proc Natl Acad Sci U S A (1993) 1.17

Prevalence of human papillomavirus DNA in cutaneous neoplasms from renal allograft recipients supports a possible viral role in tumour promotion. Br J Cancer (1994) 1.16

Continued use of non-steroidal anti-inflammatory drugs: an index of clinical efficacy. Br J Clin Pharmacol (1978) 1.14

Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis. Ann Rheum Dis (1997) 1.13

Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) (2003) 1.11

Ruptured abdominal aortic aneurysm. Surgical management. Arch Surg (1968) 1.11

Arteriosclerotic aneurysm of anomalous right subclavian artery. J Thorac Cardiovasc Surg (1970) 1.11

Rehabilitation status: a measure of medicosocial dysfunction. Lancet (1988) 1.10

Burns because of epilepsy. Br Med J (Clin Res Ed) (1988) 1.10

Site-specific melanocytic naevus counts as predictors of whole body naevi. Br J Dermatol (1988) 1.09

Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? Ann Rheum Dis (1999) 1.09

Does the order of second-line treatment in rheumatoid arthritis matter? Br Med J (Clin Res Ed) (1982) 1.09

Sulphasalazine hepatotoxicity: lack of a hypersensitivity response. Ann Rheum Dis (1986) 1.09

Arthropathy induced by beta blockade. Br Med J (Clin Res Ed) (1984) 1.09

The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. Clin Exp Immunol (1996) 1.08

Gold induced aplastic anaemia unresponsive to G-CSF. Ann Rheum Dis (1993) 1.08

Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? Ann Rheum Dis (1993) 1.08

Sternal wound complications. Management and results. J Thorac Cardiovasc Surg (1980) 1.08

Outstanding issues in use of disease-modifying agents in rheumatoid arthritis. Lancet (1999) 1.07

Sweet's syndrome and pyoderma gangrenosum associated with ulcerative colitis. Acta Derm Venereol (1985) 1.07

Mitral valve replacement. Review of seven years' experience. Am J Cardiol (1969) 1.07

The relationship of sulfoxidation status to efficacy and toxicity of penicillamine in the treatment of rheumatoid arthritis. Arthritis Rheum (1990) 1.07

Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol (1986) 1.07

Early cellular reactions induced by dinitrochlorobenzene in sensitized human skin. Br J Dermatol (1984) 1.06

The characteristics of urticaria in 390 patients. Br J Dermatol (1998) 1.06